Adolescents and adults with eosinophilic esophagitis improved with dupilumab regardless of whether they were practicing food ...

In this randomized, placebo-controlled replicate trial, depemokimab decreased the annual rate of exacerbations among patients ...

Eosinophilic esophagitis (EoE) is a chronic esophageal inflammatory disease of undetermined pathophysiology that results in dense mucosal eosinophilia and esophageal dysfunction. In childhood ...

Treatment for eosinophilic esophagitis often involves collaboration between specialists, but patients face challenges in ...

Gastrointestinal involvement is common among patients with EGPA, with eosinophilic tissue infiltration, weight loss, and myalgia identified as significant predictors.

It’s not known why some people develop EG/EoD, but many people with the condition also have a history of allergies. It may take time for EG/EoD to be diagnosed, which can be frustrating and difficult ...

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...

Background & Aims: Eosinophils are the main inflammatory effector cells that damage gastrointestinal tissue in eosinophilic gastrointestinal diseases (EGIDs). Activation of the OX40 pathway aggravates ...

According to data from a retrospective, observational study, both incidence and prevalence of eosinophilic esophagitis (EoE) are higher than previously reported. This data was presented at the 2025 ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare form of vasculitis, meaning it causes inflammation in small and medium sized blood vessels, which can result in damage to organs ...